Peer-reviewed veterinary case report
Cilobradine effects in cats with first heart failure episode
By Riesen, S C et al.·Published in Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2022·Department for Companion Animals and Horses·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of cilobradine in cats with a first episode of congestive heart failure due to primary cardiomyopathy.
- Species:
- cat
Plain-English summary
A group of cats with heart failure due to heart muscle disease (cardiomyopathy) were treated with a medication called cilobradine to see if it would help them live longer or feel better compared to a placebo. The study involved 367 cats, and while cilobradine did lower their heart rates, it didn't significantly improve their overall health or survival time compared to those who received the placebo. In fact, cats on cilobradine had a shorter time to serious heart-related issues. Unfortunately, this treatment didn't provide the hoped-for benefits for these cats.
People also search for: cat heart failure treatment · cilobradine for cats · congestive heart failure in cats · cat cardiomyopathy symptoms
Abstract
INTRODUCTION: Heart rate (HR) is often elevated in cats with cardiomyopathies (CMPs). Pharmacologic modulation of HR may reduce cardiac morbidity and mortality. OBJECTIVES: To investigate the effects of cilobradine vs. placebo, regarding time to cardiac mortality or morbidity in cats with first episode of congestive heart failure (CHF) due to primary CMP. ANIMALS: Three hundred and sixty-seven client-owned cats with primary CMP that had presented with a first episode of CHF at 50 centers in Europe. Per-protocol population comprised 193 cats (n = 89 cilobradine, n = 104 placebo). An interim analysis for futility was planned. METHODS: Prospective, randomized, placebo-controlled, double-blinded, multicenter clinical trial. Primary outcome variable was the time to a composite of cardiac mortality or cardiac morbidity. RESULTS: Median time to primary outcome was 84 days (95% confidence interval [CI]: 63-219 days) in the cilobradine group (CG) and 203 days in the placebo group (95% CI: 145-377 days) with observed hazard ratio of 1.44, indicating a higher hazard for the CG (P = 0.057). Mean HR was 28 beats per minute (bpm) lower at Day 7 (P < 0.0001) and remained 29 bpm lower at Day 360 (P = 0.026) in the CG than that in the placebo group. Although the number of adverse events did not differ, there were more serious adverse events in the CG. CONCLUSIONS: Heart rate reduction by cilobradine in cats with a first episode of CHF due to primary CMP did not reduce cardiac mortality and morbidity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35366640/